Celeris Therapeutics

About:

Harnessing deep learning and lab automation to accelerate drug discovery in targeted protein degradation.

Website: https://www.celeristx.com

Twitter/X: celeristx

Top Investors: European Innovation Council, R42 Group, APEX Ventures, Pace Ventures Enigma, Longevitytech.fund

Description:

Celeris Therapeutics is an AI-first drug discovery company that develops proximity-inducing compounds (PICs), focusing on PIC degraders for diseases with high unmet medical needs, such as Parkinson's and various types of cancers. Celeris Therapeutics has developed the Celeris One platform to streamline the development of degraders and, most importantly, rationalize their design. Celeris One leverages structure-based geometric deep learning to prioritize specific E3 ligases, design linkers, and select the most active compounds for synthesis. An in-house automated lab quickly generates experimental data for additional optimization cycles. Celeris Therapeutics collaborates with pharma and biotech companies to jointly discover and develop small-molecule degrader medicines for all therapeutic areas. It is also developing an in-house drug pipeline. Celeris Therapeutics has offices in Menlo Park, CA, and Graz, Austria.

Total Funding Amount:

16.5M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Menlo Park, California, United States

Founded Date:

2021-01-01

Contact Email:

hi(AT)celeristx.com

Founders:

Christopher Trummer

Number of Employees:

11-50

Last Funding Date:

2022-10-19

IPO Status:

Private

© 2024 MyAiNote.com